Mathematical modeling of drug resistance due to KRAS mutation in colorectal cancer
From MaRDI portal
Publication:304779
DOI10.1016/J.JTBI.2015.10.019zbMATH Open1343.92244OpenAlexW2113972773WikidataQ50777138 ScholiaQ50777138MaRDI QIDQ304779FDOQ304779
Authors: Sheema Sameen, Roberto Barbuti, Paolo Milazzo, Antonio Cerone, Marzia Del Re, Romano Danesi 
Publication date: 26 August 2016
Published in: Journal of Theoretical Biology (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1016/j.jtbi.2015.10.019
Recommendations
- A mathematical model for progression and heterogeneity in colorectal cancer dynamics
- A mathematical model for progression and heterogeneity in colorectal cancer dynamics
- Mathematical modeling of gastro-intestinal metastasis resistance to tyrosine kinase inhibitors
- An elementary mathematical modeling of drug resistance in cancer
- A mathematical model of drug resistance: Heterogeneous tumors
- A mathematical model of the effects of drug resistance in cancer chemotherapy
- Mathematical model of colorectal cancer initiation
- Stochastic modeling of drug resistance in cancer
- Modeling the transfer of drug resistance in solid tumors
Cites Work
Cited In (5)
- Mathematical modeling and analysis of ErbB3 and EGFR dimerization process for the gefitinib resistance
- Overcoming drug resistance to BRAF inhibitor
- A mathematical model for progression and heterogeneity in colorectal cancer dynamics
- Phase-specific cancer-immune model considering acquired resistance to therapeutic agents
- Mathematical modeling of the dimerization of EGFR and ErbB3 in lung adenocarcinoma
Uses Software
This page was built for publication: Mathematical modeling of drug resistance due to KRAS mutation in colorectal cancer
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q304779)
